Cisplatin (cis-diaminedichloroplatinum II, CDDP) is extensively used for the treatment of several cancers. Its major side effect; namely, nephrotoxicity, is a dose-limiting factor in CDDP therapy.
Protective Effects of Capsaicin against Cisplatin-Induced Nephrotoxicity in Rats
Yuka SHIMEDA, a,b Yoshihiko HIROTANI,* ,a Youko AKIMOTO, a Kyoko SHINDOU, a,c Yoshio IJIRI, moved, washed with ice-cold saline, and blotted with a piece of filter paper. Then, they were weighed, decapsulated and homogenized with a Potter-Elvehjem homogenizer in icecold 20 mM phosphate buffer (pH 7.4, 1 : 5 wt./vol.) solution.
The homogenate was centrifuged at 3000ϫg for 10 min at 4°C. The supernatant was collected and stored frozen at Ϫ80°C; this sample was tested for the activities of SOD and products of lipid peroxidation. For GSH analysis, a portion of kidney tissues were homogenized in 5% ice-cold 5-sulfosalicylic acid dehydrate (Sigma, MO, U.S.A.) to yield a 10% (w/v) homogenate and centrifuged at 8000ϫg for 10 min at 4°C. The supernatant was collected and stored frozen at Ϫ80°C for glutathione assay. The changes in urinary volume were measured at 12-h intervals, and the changes in the body weight were also determined throughout the experiments. Biochemical Assays The plasma creatinine and blood urea nitrogen (BUN) were measured according to the methods of Bonsnes and Taussky 15) and Searcy et al. 16) respectively, using diagnostic kits (Wako Pure Chemicals Industries Ltd., Osaka, Japan). Tissue-reduced total GSH content and SOD activity were determined according to the methods of Ellman, 17) and McCord and Fridovich 18) and the tissue lipid peroxidation in terms of Malonaldehyde (MDA) production was determined according to the method of Esterbauer et al. 19) Protein determinations were performed using the method of Lowry et al.
20)
Statistical Analysis The experimental data are expressed as meanϮS.D. The data were analyzed by the Student t-test. The differences were considered to be statistically significant when pϽ0.05.
RESULTS
The effects of Cap on CDDP-induced nephrotoxicity were evaluated by the changes in body weight. The control group and those that received only Cap showed a relatively constant increase in the body weight throughout the experimental periods (data not shown). A statistically significant difference in weight loss was detected 7 d after CDDP injection in the CDDP-treated group as compared to the control groups (pϽ 0.05) (Fig. 1) . The decrease in body weight in the CDDPtreated animals shown in Fig. 1 was not inhibited by oral treatment with Cap.
No differences in the kidney weight as a percentage of the total body weight were observed between the Cap and control groups (Table 1) . Treatment of the normal rats by CDDP resulted in a 132% increase in kidney weight as a percentage of the total body weight as compared with the control group (pϽ0.05) ( Table 1) . Also, the administration of Cap along with CDDP decreased the kidney weight to normal levels (pϽ0.05 as compared to the CDDP-treated group) ( Table 1) .
Treatment with CDDP resulted in significant increases in the urine volume, serum creatinine, and BUN by about 315, 797, and 556% in comparison with the control rats, respectively ( Table 1 ). The fourth group exhibited a significant decrease in the urine volume, serum creatinine, and BUN by about 28, 77, and 62% in comparison with the CDDP-treated normal rats, even though they were not as low as the values of the control group (pϽ0.05) ( Table 1) .
CDDP treatment produced a significant (pϽ0.05) reduction in the kidney GSH content and SOD activity and a significant elevation in the kidney MDA production at all time points in comparison with the values at 0 h, respectively (Figs. 2-4). CDDP plus Cap treatment increased the renal GSH but not significantly. However, such treatment revealed significant increases in the SOD activity in the animals sacrificed at 24, 48, and 72 h after CDDP injection (Fig. 3) , and 1636 Vol. 28, No. 9 significant decreases in the kidney MDA production in the animals killed at 6 h after CDDP plus Cap treatment as compared with those treated with CDDP alone (Fig. 4) .
DISCUSSION
In this study, the CDDP-induced kidney damage was characterized by significant increases in the kidney weight as a percentage of the total body weight, urine volume, serum creatinine, and BUN in comparison with the control group (Table 1) . Morphologic alterations in the kidneys after injection of CDDP (5 mg/kg) were characterized by selective proximal tubular damage including a moderate degree of necrosis and a formation of proteinaceous casts of the tubular cells (data not shown). Also, CDDP treatment resulted in significant decreases in the kidney GSH content and SOD activity and a significant increase in the MDA production in comparison to the values at 0 h (Figs. 2-4) . These data are in good agreement with previous studies. 4, [12] [13] [14] [21] [22] [23] Although the mechanism of CDDP-induced nephrotoxicity is exactly unknown, several studies have suggested that the nephrotoxicity is induced by lipid peroxidation and free radicals. On the other hand, many antioxidants have been shown to be protective against CDDP-induced nephrotoxicity. [12] [13] [14] Also, various free radical scavengers have been shown to be effective in protection against CDDP-induced nephrotoxicity, and treatment with such agents provides significant protection against CDDP-induced acute renal failure. 4, 24) Cap and its analogues have more effective antioxidant activity. [7] [8] [9] [10] 25) Cap was also found to scavenge radicals at/near the membrane surface and in the interior of the phospholipid membrane.
10) Furthermore, Lee et al. reported that rats treated with Cap (3 mg/kg body wt.) for 3 d showed a reduction in oxidative stress that was measured as malondialdehyde in the liver, lung, kidney and muscle. 26 ) Therefore, we investigated the possible protective effect of Cap against nephrotoxicity induced by CDDP.
Treatment with Cap alone (10 mg/kg/d, p.o.) for 6 consecutive days induced a certain degree of changes in the measured biochemical parameters (Table 1) . However, administration of Cap (10 mg/kg/d, p.o.) for 6 consecutive days after a single dose of CDDP (5 mg/kg, i.p.) rendered the rats less susceptible to kidney damage induced by treatment with CDDP. Cap significantly prevented the elevation of CDDPinduced kidney weight as a percentage of the total body weight, urine volume, serum creatinine, and BUN at the times points selected in our study. In addition, Cap treatment for rats injected with CDDP produced a significant increase in the kidney SOD activity and a significant decrease in the kidney MDA production in comparison with the CDDPtreated rats.
The concentration of MDA as a result of lipid peroxidation shows an increase in the CDDP treated group. The decreased SOD activity can cause the initiation and progression of lipid peroxidation in the CDDP treated group. This decreased activity may be due to loss of copper and zinc, which are essential for the enzyme activity or reactive oxygen species-induced enzyme inactivation. 27) Recent evidences 2, 4, 24) have indicated that the free radicals and reactive oxygen species are involved in the CDDP-induced oxidative stress because of depletion of the GSH concentration and decreased antioxidant enzyme activity in the kidneys. These observations also support the hypothesis that part of the mechanism of nephrotoxicity in the CDDP-treated animals is related to depletion of antioxidants. Cap treatment (10 mg/kg body wt., p.o.) for the CDDP-treated rats could significantly prevent depletion (or damage) of the renal antioxidants. Also, this might be attributed to the role of Cap as an antioxidant against lipid peroxidation.
Administration of Cap to rats for 6 d after CDDP treatment significantly mitigated CDDP-induced nephrotoxicity (pϽ0.05) ( Table l) . This was manifested by the improvement in all biochemical variables that was noticed in the rats with CDDP-induced nephrotoxicity. Also, the body weight of the CDDP-treated rats that received Cap reflected the protective effect of Cap against the CDDP-induced nephrotoxicity (Fig.  1) . From the results of the present study the renal GSH content and the SOD activity significantly decreased and the renal MDA production significantly increased in CDDP treated rats compared to the values at 0 h, and the SOD activity only was remarkably improved compared to the results of the renal GSH and MDA content by co-treatment with Cap. Our studies demonstrated that Cap is potent in protecting against free radical damage induced by CDDP. CDDP gener- ates active oxygen species such as superoxide anion and hydroxyl radical 28, 29) and stimulates renal lipid peroxidation. 23, [30] [31] [32] The free radical scavengers SOD are reported to provide partial protection against CDDP-induced structural and functional alteration in rats. 4) And also, Nishikawa et al reported that the cationic superoxide dismutase derivative rapidly and selectively accumulates in and around proximal tubule cells and effectively dismutes superoxide radicals in site. 33) On other hand, Cap showed the radical scavenging activity by measuring in the oxidation of lipid in vitro system. 9, 25) Moreover, Cap was reported to be effective against the oxidant stress by countering the depleted antioxidant molecules and antioxidant enzyme in erythrocytes and liver of rats.
34) The exact roles of free radicals in CDDP-induced nephrotoxicity and the mechanisms for the beneficial effects of free radical scavengers have not been fully proved.
2) However, this suggests that Cap protects against oxidative damage induced by CDDP due, at least in part, to its radical scavenging capacity. Furthermore, it was reported that the radical scavenging site of Cap is the C7-benzyl carbon 10) and Cap inhibited the oxidation almost as effectively as a-tocopherol in liposomal membrane. 9) Although little is known about such direct interactions, Cap might prevent the CDDP-induced acute renal failure through attenuation of the renal tubular damage or enhancement of the regenerative response in the damaged tubular cells.
In conclusion, Cap markedly reduced the CDDP-induced nephrotoxicity and suggests that Cap confers protection against the oxidative damage associated with CDDP. This mechanism may be reasonably attributed to its radical scavenging activity, to its SOD activating property, and/or to its regulatory activity on renal function. Further studies on tumor-bearing animals are necessary to clarify whether Cap under the conditions used in the present investigation, may not affect the therapeutic efficacy of CDDP.
